Endocrine and intracrine sources of androgens in women:: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone

被引:428
|
作者
Labrie, F
Luu-The, V
Labrie, C
Bélanger, A
Simard, J
Lin, SX
Pelletier, G
机构
[1] CHU Laval, Mol Endocrinol & Oncol Res Ctr, Quebec City, PQ G1V 4G2, Canada
[2] Univ Laval, Quebec City, PQ G1V 4G2, Canada
关键词
POST-MENOPAUSAL WOMEN; HUMAN 17-BETA-HYDROXYSTEROID DEHYDROGENASE; BONE-MINERAL DENSITY; AMINO-ACID-SEQUENCE; 7,12-DIMETHYLBENZ(A)ANTHRACENE-INDUCED MAMMARY-TUMORS; DOSE MEDROXYPROGESTERONE ACETATE; CONGENITAL ADRENAL-HYPERPLASIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RAT VENTRAL PROSTATE; SEX-HORMONE LEVELS;
D O I
10.1210/er.2001-0031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serum androgens as well as their precursors and metabolites decrease from the age of 30-40 yr in women, thus suggesting that a more physiological hormone replacement therapy at menopause should contain an androgenic compound. It is important to consider, however, that most of the androgens in women, especially after menopause, are synthesized in peripheral intracrine tissues from the inactive precursors dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEA-S) of adrenal origin. Much progress in this new area of endocrine physiology called intracrinology has followed the cloning and characterization of most of the enzymes responsible for the transformation of DHEA and DHEA-S into androgens and estrogens in peripheral target tissues, where the locally produced sex steroids are exerting their action in the same cells in which their synthesis takes place without significant diffusion into the circulation, thus seriously limiting the interpretation of serum levels of active sex steroids. The sex steroids made in peripheral tissues are then inactivated locally into more water-soluble compounds that diffuse into the general circulation where they can be measured. In a series of animal models, androgens and DHEA have been found to inhibit breast cancer development and growth and to stimulate bone formation. In clinical studies, DHEA has been found to increase bone mineral density and to stimulate vaginal maturation without affecting the endometrium, while improving well-being and libido with no significant side effects. The advantage of DHEA over other androgenic compounds is that DHEA, at physiological doses, is converted into androgens and/or estrogens only in the specific intracrine target tissues that possess the appropriate physiological enzymatic machinery, thus limiting the action of the sex steroids to those tissues possessing the tissue-specific profile of expression of the genes responsible for their formation, while leaving the other tissues unaffected and thus minimizing the potential side effects observed with androgens or estrogens administered systemically.
引用
收藏
页码:152 / 182
页数:31
相关论文
共 34 条
  • [31] Neoadjuvant chemotherapy vs neoadjuvant endocrine therapy in ER/PR positive HER-2 negative post-menopausal women with breast cancer, is one superior than other? A NCDB analysis
    Basnet, Alina
    Wang, Dongliang
    Sivapiragasam, Abirami
    CANCER RESEARCH, 2018, 78 (04)
  • [32] Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-na⟨ve advanced breast cancer
    Johnston, Stephen
    Basik, Mark
    Hegg, Roberto
    Lausoontornsiri, Wirote
    Grzeda, Lukasz
    Clemons, Mark
    Dreosti, Lydia
    Mann, Helen
    Stuart, Mary
    Cristofanilli, Massimo
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 160 (01) : 91 - 99
  • [33] Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer
    Stephen Johnston
    Mark Basik
    Roberto Hegg
    Wirote Lausoontornsiri
    Lukasz Grzeda
    Mark Clemons
    Lydia Dreosti
    Helen Mann
    Mary Stuart
    Massimo Cristofanilli
    Breast Cancer Research and Treatment, 2016, 160 : 91 - 99
  • [34] Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer-CALGB 40302 (Alliance)
    Burstein, Harold J.
    Cirrincione, Constance T.
    Barry, William T.
    Chew, Helen K.
    Tolaney, Sara M.
    Lake, Diana E.
    Ma, Cynthia
    Blackwell, Kimberly L.
    Winer, Eric P.
    Hudis, Clifford A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) : 3959 - U247